ABLI — Abliva AB Share News
0.000.00%
Last trade - 00:00- SEK467.94m
- SEK435.27m
Brief: Abliva Q3 Loss Before Tax Narrows To SEK 10.1 Mln
Brief: Abliva Gets Positive Regulatory Feedback On KL1333 Phase II/III Study Plan
Brief: Abliva Says Intends To Start A Pivotal Kl1333 Study Second Half 2021
Brief: Abliva Q2 Loss Before Tax Narrows To KSEK 20,312
Brief: NeuroVive Pharmaceutical Q1 Loss Before Tax Widens To KSEK 16,537
Brief: Neurovive Pharmaceutical AB - Q4 Pre-Tax Loss Sek 27.1 Million Versus Loss Sek 20.0 Million Year Ago
Brief: Neurovive Proposes A Rights Issue Of SEK 74 Mln
Brief: NeuroVive Announces Settlement In Dispute With CicloMulsion
Brief: NeuroVive Pharmaceutical Q3 Pre-tax Loss Up At SEK 15.3 Mln
Brief: NeuroVive Pharmaceutical Q2 Pre-Tax Loss Narrows To SEK 20.8 Mln
Brief: Neurovive's NeuroSTAT Project Receives FDA Fast Track Designation
Brief: NeuroVive Jan-March Loss Before Tax Widens To SEK 13.8 Million
Brief: Neurovive Announces Ruling From Supreme Court In Case Between The Company And Ciclomulsion AG
Brief: Neurovive Pharmaceutical Proposes No Dividend For FY 2018
Brief: Neurovive Receives Sek 28.2 Million In A Directed New Share Issue
Brief: Neurovive Pharmaceutical Q4 Pre-Tax Loss Widens To SEK 20.0 Mln
Brief: Neurovive Pharmaceutical Q4 Pre-Tax Loss Widens To SEK 20 Million
Brief: Neurovive Enters Commercial Partnership With Oroboros Instruments
Brief: Neurovive Gets About SEK 99.0 Mln In Share Issue Proceeds